{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:34:35Z","timestamp":1789684475974,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Catholic Medical Center Research Foundation","award":["Program year of 2018"],"award-info":[{"award-number":["Program year of 2018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Currently, there is no appropriate treatment option for patients with sorafenib-resistant hepatocellular carcinoma (HCC). Meanwhile, pronounced anticancer activities of newly-developed mitochondria-accumulating self-assembly peptides (Mito-FF) have been demonstrated. This study intended to determine the anticancer effects of Mito-FF against sorafenib-resistant Huh7 (Huh7-R) cells. Compared to sorafenib, Mito-FF led to the generation of relatively higher amounts of mitochondrial reactive oxygen species (ROS) as well as the greater reduction in the expression of antioxidant enzymes (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Mito-FF was found to significantly promote cell apoptosis while inhibiting cell proliferation of Huh7-R cells. Mito-FF also reduces the expression of antioxidant enzymes while significantly increasing mitochondrial ROS in Huh7-R cells. The pro-apoptotic effect of Mito-FFs for Huh7-R cells is possibly caused by their up-regulation of mitochondrial ROS, which is caused by the destruction of the mitochondria of HCC cells.<\/jats:p>","DOI":"10.1038\/s41598-020-79536-z","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:26:43Z","timestamp":1610537203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Tae Ho","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Jeena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ok-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Joong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha-Eun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Hyoung","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Say-June","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"79536_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"79536_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","volume":"12","author":"GM Keating","year":"2017","unstructured":"Keating, G. M. Sorafenib: A review in hepatocellular carcinoma. Target Oncol. 12, 243\u2013253 (2017).","journal-title":"Target Oncol."},{"key":"79536_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5306\/wjco.v8.i3.203","volume":"8","author":"IA Ziogas","year":"2017","unstructured":"Ziogas, I. A. & Tsoulfas, G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J. Clin. Oncol. 8, 203\u2013213 (2017).","journal-title":"World J. Clin. Oncol."},{"key":"79536_CR4","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129\u20133140 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"79536_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1872-034X.2012.01113.x","volume":"43","author":"A Gauthier","year":"2013","unstructured":"Gauthier, A. & Ho, M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol. Res. 43, 147\u2013154 (2013).","journal-title":"Hepatol. Res."},{"key":"79536_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/cco.2018.10.10","volume":"7","author":"P Boland","year":"2018","unstructured":"Boland, P. & Wu, J. Systemic therapy for hepatocellular carcinoma: beyond sorafenib. Chin. Clin. Oncol. 7, 50 (2018).","journal-title":"Chin. Clin. Oncol."},{"key":"79536_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4251\/wjgo.v10.i5.108","volume":"10","author":"M Contratto","year":"2018","unstructured":"Contratto, M. & Wu, J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J. Gastrointest. Oncol. 10, 108\u2013114 (2018).","journal-title":"World J. Gastrointest. Oncol."},{"key":"79536_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3350\/cmh.2017.0108","volume":"23","author":"IE Dika","year":"2017","unstructured":"Dika, I. E. & Abou-Alfa, G. K. Treatment options after sorafenib failure in patients with hepatocellular carcinoma. Clin. Mol. Hepatol. 23, 273\u2013279 (2017).","journal-title":"Clin. Mol. Hepatol."},{"key":"79536_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3390\/cancers11060841","volume":"11","author":"D Li","year":"2019","unstructured":"Li, D. et al. Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. Cancers Basel 11, 841 (2019).","journal-title":"Cancers Basel"},{"issue":"10","key":"79536_CR10","doi-asserted-by":"publisher","first-page":"11022","DOI":"10.1021\/acsnano.9b02522","volume":"13","author":"MT Jeena","year":"2019","unstructured":"Jeena, M. T. et al. Heterochiral assembly of amphiphilic peptides inside the mitochondria for supramolecular cancer therapeutics. ACS Nano 13(10), 11022\u201311033 (2019).","journal-title":"ACS Nano"},{"key":"79536_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41467-017-00047-z","volume":"8","author":"MT Jeena","year":"2017","unstructured":"Jeena, M. T. et al. Mitochondria localization induced self-assembly of peptide amphiphiles for cellular dysfunction. Nat. Commun. 8, 26 (2017).","journal-title":"Nat. Commun."},{"key":"79536_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","volume":"11","author":"SE Weinberg","year":"2015","unstructured":"Weinberg, S. E. & Chandel, N. S. Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol. 11, 9\u201315 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"79536_CR13","doi-asserted-by":"publisher","first-page":"19775","DOI":"10.3390\/molecules201119658","volume":"20","author":"S Marchesan","year":"2015","unstructured":"Marchesan, S., Vargiu, A. V. & Styan, K. E. The Phe-Phe Motif for peptide self-assembly in nanomedicine. Molecules 20, 19775\u201319788 (2015).","journal-title":"Molecules"},{"key":"79536_CR14","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1039\/b915765b","volume":"39","author":"X Yan","year":"2010","unstructured":"Yan, X., Zhu, P. & Li, J. Self-assembly and application of diphenylalanine-based nanostructures. Chem. Soc. Rev. 39, 1877\u20131890 (2010).","journal-title":"Chem. Soc. Rev."},{"key":"79536_CR15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.yexcr.2009.12.008","volume":"316","author":"LX Zhang","year":"2010","unstructured":"Zhang, L. X., Seitz, L. C., Abramczyk, A. M. & Chan, C. Synergistic effect of cAMP and palmitate in promoting altered mitochondrial function and cell death in HepG2 cells. Exp. Cell Res. 316, 716\u2013727 (2010).","journal-title":"Exp. Cell Res."},{"key":"79536_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000327563","volume":"29","author":"HY Kim","year":"2011","unstructured":"Kim, H. Y. & Park, J. W. Molecularly targeted therapies for hepatocellular Carcinoma: Sorafenib as a stepping stone. Digest. Dis. 29, 303\u2013309 (2011).","journal-title":"Digest. Dis."},{"key":"79536_CR17","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.3748\/wjg.v20.i15.4151","volume":"20","author":"K Miyahara","year":"2014","unstructured":"Miyahara, K., Nouso, K. & Yamamoto, K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J. Gastroenterol. 20, 4151\u20134159 (2014).","journal-title":"World J. Gastroenterol."},{"key":"79536_CR18","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.3390\/ijms21176126","volume":"21","author":"DJ Kim","year":"2020","unstructured":"Kim, D. J. et al. Novel therapeutic application of self-assembly peptides targeting the mitochondria in in vitro and in vivo experimental models of gastric cancer. Int. J. Mol. Sci. 21, 6126 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"79536_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bip.21328","volume":"94","author":"H Cui","year":"2010","unstructured":"Cui, H., Webber, M. J. & Stupp, S. I. Self-assembly of peptide amphiphiles: From molecules to nanostructures to biomaterials. Biopolymers 94, 1\u201318 (2010).","journal-title":"Biopolymers"},{"key":"79536_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nantod.2016.02.004","volume":"11","author":"N Habibi","year":"2016","unstructured":"Habibi, N., Kamaly, N., Memic, A. & Shafiee, H. Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery. Nano Today 11, 41\u201360 (2016).","journal-title":"Nano Today"},{"key":"79536_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/187221111794109510","volume":"5","author":"P Kumar","year":"2011","unstructured":"Kumar, P. et al. Self-assembling peptides: Implications for patenting in drug delivery and tissue engineering. Recent Pat. Drug Deliv. Formul. 5, 24\u201351 (2011).","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"79536_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1126\/science.1082387","volume":"300","author":"M Reches","year":"2003","unstructured":"Reches, M. & Gazit, E. Casting metal nanowires within discrete self-assembled peptide nanotubes. Science 300, 625\u2013627 (2003).","journal-title":"Science"},{"key":"79536_CR23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.nantod.2015.09.001","volume":"10","author":"JF Shi","year":"2015","unstructured":"Shi, J. F. & Xu, B. Nanoscale assemblies of small molecules control the fate of cells. Nano Today 10, 615\u2013630 (2015).","journal-title":"Nano Today"},{"key":"79536_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/IJN.S117501","volume":"12","author":"L Sun","year":"2017","unstructured":"Sun, L., Zheng, C. & Webster, T. J. Self-assembled peptide nanomaterials for biomedical applications: Promises and pitfalls. Int. J. Nanomed. 12, 73\u201386 (2017).","journal-title":"Int. J. Nanomed."},{"key":"79536_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-13-9791-2_1","volume":"1174","author":"G Meisl","year":"2019","unstructured":"Meisl, G. et al. Dynamics and control of peptide self-assembly and aggregation. Adv. Exp. Med. Biol. 1174, 1\u201333 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"79536_CR26","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.2147\/IJN.S166403","volume":"13","author":"F Qiu","year":"2018","unstructured":"Qiu, F., Chen, Y. Z., Tang, C. K. & Zhao, X. J. Amphiphilic peptides as novel nanomaterials: Design, self-assembly and application. Int. J. Nanomed. 13, 5003\u20135022 (2018).","journal-title":"Int. J. Nanomed."},{"key":"79536_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-981-13-9791-2_2","volume":"1174","author":"L Yu","year":"2019","unstructured":"Yu, L., Yang, Y. & Wang, C. Peptide self-assembly and its modulation: Imaging on the nanoscale. Adv. Exp. Med. Biol. 1174, 35\u201360 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"79536_CR28","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1039\/b915923c","volume":"39","author":"X Zhao","year":"2010","unstructured":"Zhao, X. et al. Molecular self-assembly and applications of designer peptide amphiphiles. Chem. Soc. Rev. 39, 3480\u20133498 (2010).","journal-title":"Chem. Soc. Rev."},{"key":"79536_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","volume":"11","author":"WH Koppenol","year":"2011","unstructured":"Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg\u2019s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325\u2013337 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"79536_CR30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/em.20554","volume":"51","author":"MC Frantz","year":"2010","unstructured":"Frantz, M. C. & Wipf, P. Mitochondria as a target in treatment. Environ. Mol. Mutagen 51, 462\u2013475 (2010).","journal-title":"Environ. Mol. Mutagen"},{"key":"79536_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1155\/2013\/956792","volume":"1","author":"B Poljsak","year":"2013","unstructured":"Poljsak, B., Suput, D. & Milisav, I. Achieving the balance between ROS and antioxidants: When to use the synthetic antioxidants. Oxid. Med. Cell Longev. 1, 23. https:\/\/doi.org\/10.1155\/2013\/956792 (2013).","journal-title":"Oxid. Med. Cell Longev."},{"key":"79536_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/cells8040287","volume":"8","author":"C Bouchez","year":"2019","unstructured":"Bouchez, C. & Devin, A. Mitochondrial biogenesis and mitochondrial reactive oxygen species (ROS): A complex relationship regulated by the cAMP\/PKA signaling pathway. Cells 8, 287 (2019).","journal-title":"Cells"},{"key":"79536_CR33","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.bbabio.2014.02.023","volume":"1837","author":"ED Yoboue","year":"2014","unstructured":"Yoboue, E. D. et al. The role of mitochondrial biogenesis and ROS in the control of energy supply in proliferating cells. Biochim. Biophys. Acta 1837, 1093\u20131098 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"79536_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2015.06.019","volume":"367","author":"J Chen","year":"2015","unstructured":"Chen, J. et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 367, 1\u201311 (2015).","journal-title":"Cancer Lett."},{"key":"79536_CR35","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1111\/febs.14641","volume":"285","author":"M Mishra","year":"2018","unstructured":"Mishra, M., Jayal, P., Karande, A. A. & Chandra, N. Identification of a co-target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach. Febs. J. 285, 3977\u20133992 (2018).","journal-title":"Febs. J."},{"key":"79536_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40880-019-0362-z","volume":"39","author":"X You","year":"2019","unstructured":"You, X. et al. Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis. Cancer Commun. (Lond) 39, 17 (2019).","journal-title":"Cancer Commun. (Lond)"},{"key":"79536_CR37","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/ars.2007.1957","volume":"10","author":"D Trachootham","year":"2008","unstructured":"Trachootham, D., Lu, W. Q., Ogasawara, M. A., Valle, N. R. D. & Huang, P. Redox regulation of cell survival. Antioxid Redox Sign. 10, 1343\u20131374 (2008).","journal-title":"Antioxid Redox Sign."},{"key":"79536_CR38","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ijc.23086","volume":"122","author":"M Fraser","year":"2008","unstructured":"Fraser, M., Bai, T. & Tsang, B. K. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int. J. Cancer 122, 534\u2013546 (2008).","journal-title":"Int. J. Cancer"},{"key":"79536_CR39","first-page":"7081","volume":"63","author":"M Fraser","year":"2003","unstructured":"Fraser, M. et al. p53 is a determinant of X-linked inhibitor of apoptosis protein\/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 63, 7081\u20137088 (2003).","journal-title":"Cancer Res."},{"key":"79536_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12935-019-0910-2","volume":"19","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR\/PI3K\/AKT signaling. Cancer Cell Int. 19, 188 (2019).","journal-title":"Cancer Cell Int."},{"key":"79536_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/cdd.2017.169","volume":"25","author":"BJ Aubrey","year":"2018","unstructured":"Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J. & Strasser, A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?. Cell Death Differ. 25, 104\u2013113 (2018).","journal-title":"Cell Death Differ."},{"key":"79536_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/jpet.110.175786","volume":"337","author":"KF Chen","year":"2011","unstructured":"Chen, K. F. et al. Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 337, 155\u2013161 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"79536_CR43","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1016\/j.bbamcr.2016.09.023","volume":"1863","author":"A Labno","year":"2016","unstructured":"Labno, A., Tomecki, R. & Dziembowski, A. Cytoplasmic RNA decay pathways\u2014Enzymes and mechanisms. Biochim. Biophys. Acta 1863, 3125\u20133147 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"79536_CR44","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/emboj\/17.6.1675","volume":"17","author":"C Scaffidi","year":"1998","unstructured":"Scaffidi, C. et al. Two CD95 (APO-1\/Fas) signaling pathways. EMBO J. 17, 1675\u20131687 (1998).","journal-title":"EMBO J."},{"key":"79536_CR45","first-page":"2022","volume":"115","author":"K Palanivel","year":"2014","unstructured":"Palanivel, K., Kanimozhi, V., Kadalmani, B. & Akbarsha, M. A. Verrucarin a induces apoptosis through ROS-mediated EGFR\/MAPK\/Akt signaling pathways in MDA-MB-231 breast cancer cells. J. Cell Biochem. 115, 2022\u20132032 (2014).","journal-title":"J. Cell Biochem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79536-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79536-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79536-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T14:32:17Z","timestamp":1697553137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79536-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["79536"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-79536-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"12 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"874"}}